ctDNA as an Adjunct to Posttreatment PET for Head and Neck Cancer Recurrence Risk Assessment
Otolaryngology–Head and Neck Surgery · 2024
DOI: 10.1002/ohn.760 ↗Kurz gefasst
Fachartikel in der Zeitschrift Otolaryngology–Head and Neck Surgery, 2024. Verfasst von Saudamini J Lele und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology and Head Neck Surgery, Louisiana State University of Health Sciences, Shreveport, Louisiana, USA. Hauptthemen laut MEDLINE: Neoplasm Recurrence, Local, Head and Neck Neoplasms, Circulating Tumor DNA, Positron-Emission Tomography. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Objective
Circulating tumor DNA (ctDNA) detection is an emerging technique that identifies minimal residual disease in patients with solid tumors. ctDNA can act as an adjunct method to help overcome the limitations of positron emission tomography (PET) and select patients who are at high risk for recurrence. Study Design Retrospective Single Institutional Study.
Setting
University Hospital Setting.
Methods
Twenty‐nine patients who underwent definitive treatment for squamous cell carcinoma of the head and neck (HNSCC) from 8/2021 to 01/2023 had ctDNA levels analyzed at 1 to 3, 6, 9, and 12 months after definitive treatment. A personalized, tumor‐informed, multiplex polymerase chain reaction (PCR) next‐generation sequencing (NGS) assay was used to detect the ctDNA levels. The primary outcome was recurrence‐free probability (RFP), and the secondary outcomes were overall survival (OS), sensitivity, specificity, and the test's negative (NPV) and positive predictive values (PPV).
Results
The median age of patients was 65 years (interquartile range: 56‐69), with majority being males (n = 22, 76%). The primary sites were larynx (n = 12), oropharynx (n = 10), and oral cavity (n = 6). Posttreatment ctDNA was detected in 7 patients, all of whom had disease recurrence. ctDNA detection after definitive treatment was associated with a higher risk of disease recurrence (hazard ratio: 9.94, 95% confidence interval: 1.56‐63.3, P = .015). ctDNA identified recurrence with 100% specificity and 78% sensitivity. The NPV and PPV were 91% and 100%. PET had 78% sensitivity but only 68% specificity with 86% NPV, and 54% PPV.
Conclusion
Based on our data, ctDNA can be an excellent adjunct test for posttreatment PET and can help guide physicians in cases where PET results are inconclusive and difficult to interpret.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology and Head Neck Surgery, Louisiana State University of Health Sciences, Shreveport, Louisiana, USA.
- Feist Weiller Cancer Center, Shreveport, Louisiana, USA.
ORCID-Profile: Dauren Adilbay
Zitieren
APA
Lele, S. J., Adilbay, D., Lewis, E., Pang, J., Asarkar, A. A., & Nathan, C. O. (2024). ctDNA as an Adjunct to Posttreatment PET for Head and Neck Cancer Recurrence Risk Assessment. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.760
Vancouver
Lele SJ, Adilbay D, Lewis E, Pang J, Asarkar AA, Nathan CO. ctDNA as an Adjunct to Posttreatment PET for Head and Neck Cancer Recurrence Risk Assessment. Otolaryngology–Head and Neck Surgery. 2024. doi:10.1002/ohn.760
BibTeX
@article{Lele2024,
author = {Lele, Saudamini J and Adilbay, Dauren and Lewis, Ellen and Pang, John and Asarkar, Ameya A and Nathan, Cherie-Ann O},
title = {ctDNA as an Adjunct to Posttreatment PET for Head and Neck Cancer Recurrence Risk Assessment},
journal = {Otolaryngology–Head and Neck Surgery},
year = {2024},
doi = {10.1002/ohn.760}
}
EUVIMED